Choline for NAFLD / MASLD

Verdict: Weak evidence; not a proven NAFLD treatment

Choline reliably reverses fatty liver only when it is caused by choline deficiency (as in long-term IV nutrition); for ordinary NAFLD/MASLD the evidence that supplementing choline helps is weak and rests on a single small, open-label trial, so it should not be relied on as a treatment.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is held to Weak (C) because of a critical scope split the data force. Choline deficiency clearly drives reversible liver steatosis: a small double-blind RCT in patients on total parenteral nutrition (PMID 11531217, n=15) showed 2 g/day choline chloride raised liver CT density and lowered ALT versus placebo. That proves a human choline requirement, not that choline treats NAFLD in general.

Direct NAFLD evidence is thin and low-certainty. The only trial in a general NAFLD population (PMID 40838115, n=79, 2025) gave 2,400 mg/day phosphatidylcholine for 12 weeks and reported lower liver-fat (CAP) scores, ALT, AST and oxidative stress, with most patients improving a fibrosis stage. But it was open-label, short, and small, so bias cannot be excluded. A 200-patient cohort (PMID 38222945) was uncontrolled and combined choline with Prunus mume, so it cannot isolate choline's effect.

Regulators treat choline only as an essential nutrient, not a liver therapy: the US FDA classifies it as a NUTRIENT SUPPLEMENT and WHO/Codex lists it as a required infant-formula component. No major clinical body (NIH ODS, Mayo, Cleveland Clinic, Harvard) endorses choline supplements to treat NAFLD, and no double-blind RCT or meta-analysis supports that use. Weight loss and a Mediterranean diet remain the guideline first-line approach.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.54
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
64%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.542
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: a randomized controlled study
PMID: 40838115 2025 RCT (open-label) n = 79
Finding: Choline group reduced CAP score, ALT, AST and TBARS vs control (all p<0.001), with 66.7% achieving >=1 fibrosis stage improvement.
Government Effect size: CAP -44 dB/m within-group; TBARS -40.35% vs -2.05% control
View on PubMed
Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial
PMID: 11531217 2001 RCT (double-blind) n = 15
Finding: Choline raised liver HU density vs placebo at week 4 (13.3 vs 5.8, p=.04) and significantly lowered ALT at weeks 6-24 (p=.01-.05).
Government Effect size: Liver-spleen differential HU 10.6 (choline) vs 1.3 (placebo), p=.01
View on PubMed
Efficacy and Safety of Prunus mume and Choline in Patients with Nonalcoholic Fatty Liver Disease
PMID: 38222945 2023 Cohort n = 200
Finding: Significant reductions in cholesterol (p=0.001) and ALT/AST/GGT (p<0.001) over 24 weeks, but uncontrolled and confounded by Prunus mume co-treatment.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4d TW TFDA / 衛福部
Supportive
成年男性膽鹼建議攝取量每日至少450毫克、女性每日至少390毫克,孕婦則應提高至每日410毫克以上;膽鹼補充上限為每日3.5公克。膽鹼為「國人膳食營養素參考攝取量」第八版新增的營養素。 source↗
L4e WHO
Supportive
Codex Standard for Infant Formula (CXS 72-1981): minimum choline content 7 mg/100 kcal, maximum 50 mg/100 kcal (1.7 mg/100 kJ minimum, 12 mg/100 kJ maximum). source↗
L5e Specialty Society (condition-mapped)
Neutral
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-nafld-INT-choline-001 繁體中文版 →